Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.
Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.
Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.
Experts across the fields of lung and GI cancer share key information and insights from 2 recent OncLive biomarker consortiums.
An abstract is unavailable.
The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
Investigators studied how Mohs micrographic surgery with melanocytic immunostains affected local recurrence and mortality rates in patients with invasive melanoma.
Survey results suggest that cancer patients want financial toxicity screening to occur early, but screening preferences and practices vary.
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
